Fig. 2: Population-level impact of vaccination.
From: Efficacy, public health impact and optimal use of the Takeda dengue vaccine
a,b, Cumulative proportion of hospitalized and symptomatic cases averted over 10 years by transmission setting (expressed as the average seroprevalence in 9-year-olds), assuming efficacy against infection and disease (VI, blue) or only against disease (VS, pink) decaying for 15 years (D15), using 80% coverage across 10 years and the Brazilian demography over all serotypes (a) and by serotype (b). The dashed horizontal line marks 0 cases averted. The solid lines represent the mean and the shaded regions represent the overall uncertainty (95%CrI) derived from n = 10,000 simulations (that is, 200 posterior distribution samples × 50 stochastic simulations per sample, see Methods for details).
